⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26351384 | 0.80 | GRM2 (0.36) | — | |
| SCHEMBL16049158 | 0.80 | GRM2 (0.36) | — | |
| SCHEMBL15542498 | 0.77 | KDM4E (0.39) | — | |
| SCHEMBL22126060 | 0.77 | APLNR (0.39) | — | |
| SCHEMBL29856070 | 0.77 | CYP2C19 (0.55) | — | |
| SCHEMBL21193551 | 0.75 | KDM4E (0.42) | — | |
| SCHEMBL118781 | 0.74 | — | — | |
| SCHEMBL30876236 | 0.74 | APLNR (0.33) | — | |
| SCHEMBL31488096 | 0.74 | APLNR (0.33) | — | |
| SCHEMBL102778 | 0.74 | SMN1; SMN2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983081-B1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | claimed |
| CN-119241444-A | Aminopyrimidinamide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119176782-A | Aminopyrimidinamide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2024-12-24 | — | — | CN | claimed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | claimed |
| CN-114258318-A | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2022-03-29 | — | — | CN | claimed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | claimed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | claimed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | claimed |
| EP-2867227-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-11-21 | — | — | EP | claimed |
| EP-2867225-B1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2017-08-09 | — | — | EP | claimed |
| US-9487483-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-11-08 | — | — | US | claimed |
| US-9468661-B2 | Pyrrolidine derivatives and their use as complement pathway modulators | NOVARTIS AG (CH) | 2016-10-18 | — | — | US | claimed |
| US-20150190457-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2015-07-09 | — | — | US | claimed |
| US-20150148349-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-28 | — | — | US | claimed |
| EP-2867227-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-05-06 | — | — | EP | claimed |
| EP-2867225-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | Novartis AG (CH) | 2015-05-06 | — | — | EP | claimed |
| WO-2014002054-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | claimed |
| WO-2014002058-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | claimed |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-23 | — | — | US | disclosed |
| WO-2025264700-A1 | GIP RECEPTOR AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2025-12-26 | — | — | WO | disclosed |
| US-12365667-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-07-22 | — | — | US | disclosed |
| US-12319676-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-06-03 | — | — | US | disclosed |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| CN-119546584-A | Bicyclic compounds and their use as pest control agents | PI工业有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119241444-A | Aminopyrimidinamide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-4482487-A1 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-119233971-A | Pyridazine compound, preparation method and application thereof | 上海华汇拓医药科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119176782-A | Aminopyrimidinamide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2024-12-24 | — | — | CN | disclosed |
| US-20240398784-A1 | C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-12-05 | — | — | US | disclosed |
| CN-118892553-A | Esatitecan analogue, ligand-drug conjugate thereof and application thereof | 浙江大学 | 2024-11-05 | — | — | CN | disclosed |
| CN-114258318-B | Aminopyrimidinamide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118475567-A | Heterocyclic derivative, composition and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| CN-111315737-B | Heteroaryl compounds substituted with sulfone pyridinylalkylamides | 百时美施贵宝公司 | 2024-06-18 | — | — | CN | disclosed |
| US-11981657-B2 | Substituted benzimidazoles, their preparation and their use as pharmaceuticals | EPIGENETIX, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| CN-118019740-A | Heteroaryl derivative PARP inhibitors and uses thereof | 海思科医药集团股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-115919859-B | Pharmaceutical composition of heteroaryl derivative and application of pharmaceutical composition in medicine | 四川海思科制药有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20240002364-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-04 | — | — | US | disclosed |
| WO-2023231997-A1 | PYRIDAZINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海华汇拓医药科技有限公司 | 2023-12-07 | — | — | WO | disclosed |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| EP-3248980-B1 | JAK INHIBITOR | WUXI FORTUNE PHARMACEUTICAL CO LTD (CN) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023164538-A1 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-08-31 | — | — | WO | disclosed |
| EP-4198031-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2023-06-21 | — | — | EP | disclosed |
| US-20230120413-A1 | SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | NEOMED INSTITUTE (CA) | 2023-04-20 | — | — | US | disclosed |
| CN-113999224-B | Dihydroisoquinoline compound | 苏州爱科百发生物医药技术有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-114014854-B | Dihydroisoquinoline compound | 苏州爱科百发生物医药技术有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115919859-A | Pharmaceutical composition of heteroaryl derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-111479813-B | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2023-03-21 | — | — | CN | disclosed |
| EP-3497094-B1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-02-15 | — | — | EP | disclosed |
| WO-2022216655-A1 | N-(6-((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YI)AMINO)PYRIDAZIN-3-YL)PHENYL)CARBOXAMIDE AND (6- ((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YL)AMINO)PYRIDAZIN-3-YL)BENZAMIDE DERIVATIVES AS MACHR M4 ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | VANDERBILT UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| EP-3724192-B1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2022-08-03 | — | — | EP | disclosed |
| CN-108699032-B | Polycyclic TLR7/8 antagonists and their use in the treatment of immune disorders | 默克专利有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-111201226-B | Cyclic substituted imidazo [4,5-c ] quinoline derivatives | 辉瑞大药厂 | 2022-07-22 | — | — | CN | disclosed |
| CN-114605387-A | Substituted benzimidazoles, their preparation and their use as medicaments | 埃皮吉纳提克斯股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2022116995-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2022-06-09 | — | — | WO | disclosed |
| CN-114258318-A | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20220081430-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-03-17 | — | — | US | disclosed |
| US-20220081434-A1 | DIHYDROISOQUINOLINE COMPOUND | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-03-17 | — | — | US | disclosed |
| CN-114014854-A | Dihydroisoquinoline compound | 苏州爱科百发生物医药技术有限公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-113999224-A | Dihydroisoquinoline compound | 苏州爱科百发生物医药技术有限公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3909951-A1 | DIHYDROISOQUINOLINE COMPOUND | Suzhou Ark Biopharmaceutical Co., Ltd (CN) | 2021-11-17 | — | — | EP | disclosed |
| EP-3054947-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-17 | — | — | EP | disclosed |
| WO-2021180235-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | 四川海思科制药有限公司 | 2021-09-16 | — | — | WO | disclosed |
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2021-08-19 | — | — | US | disclosed |
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2021-08-19 | — | — | US | disclosed |
| US-11021462-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021462-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
| US-10947214-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| WO-2021032209-A1 | ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF | 四川海思科制药有限公司 | 2021-02-25 | — | — | WO | disclosed |
| US-20210002256-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-01-07 | — | — | US | disclosed |
| US-20210002255-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-01-07 | — | — | US | disclosed |
| EP-3713930-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-09-30 | — | — | EP | disclosed |
| WO-2020143604-A1 | DIHYDROISOQUINOLINE COMPOUND | 苏州爱科百发生物医药技术有限公司 | 2020-07-16 | — | — | WO | disclosed |
| CN-111410653-A | Dihydroisoquinoline compound | 苏州爱科百发生物医药技术有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-111315737-A | Sulfonylpyridinylalkylamide substituted heteroaryl compounds | 百时美施贵宝公司 | 2020-06-19 | — | — | CN | disclosed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | disclosed |
| EP-3497094-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2019-06-19 | — | — | EP | disclosed |
| WO-2019112913-A1 | BETA-2 SELECTIVE ADRENERGIC RECEPTOR AGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019103952-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-31 | — | — | WO | disclosed |
| US-20190152948-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-23 | — | — | US | disclosed |
| US-20190152948-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-23 | — | — | US | disclosed |
| EP-2867227-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-11-21 | — | — | EP | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |
| WO-2018031434-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-15 | — | — | WO | disclosed |
| US-20180037570-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| EP-2867225-B1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2017-08-09 | — | — | EP | disclosed |
| US-9573913-B2 | Cathepsin cysteine protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9487483-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-11-08 | — | — | US | disclosed |
| WO-2016173484-A1 | JAK INHIBITORS | 南京明德新药研发股份有限公司 | 2016-11-03 | — | — | WO | disclosed |
| US-9468661-B2 | Pyrrolidine derivatives and their use as complement pathway modulators | NOVARTIS AG (CH) | 2016-10-18 | — | — | US | disclosed |
| US-20160244417-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-3054947-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20150190457-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2015-07-09 | — | — | US | disclosed |
| US-20150148349-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-28 | — | — | US | disclosed |
| EP-2867227-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| EP-2867225-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | Novartis AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2015054038-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015051479-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2014002054-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| WO-2014002054-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| WO-2014002058-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |